Hims & Hers Health, Inc. is a consumer-first health and wellness platform that leverages technology to provide accessible and affordable healthcare solutions. The company offers a wide range of prescription and non-prescription products, telehealth services, and wellness content through its websites, mobile applications, and retail partnerships. Its offerings focus on addressing common health conditions, promoting lifelong wellness, and simplifying the healthcare experience for customers.
-
Online Revenue - Provides prescription and non-prescription products directly to individual customers through the company's websites and mobile applications. Includes telehealth consultations with licensed healthcare professionals who can prescribe medications when appropriate, fulfilled via licensed pharmacies.
- Prescription Products - Addresses conditions such as sexual health, hair loss, dermatology, mental health, weight loss, and primary care.
- Non-Prescription Products - Includes over-the-counter drugs, cosmetics, supplements, and wellness items such as melatonin, biotin, skincare products, sexual health products, and hair care solutions.
-
Wholesale Revenue - Sells products to wholesale partners and third-party platforms, making Hims & Hers products available in tens of thousands of retail locations across the United States.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Andrew Dudum ExecutiveBoard | CEO and Chairman | None | Co-founder of Hims, Inc. in 2016; serial entrepreneur and investor; previously co-founded Atomic Labs and other startups. Holds a B.A. in Management and Economics from Wharton. | View Report → |
Dr. Patrick Carroll Executive | Chief Medical Officer | Board Member at ChristianaCare | Rejoined Hims & Hers in December 2022; previously served as CMO for Vida Health and WHOOP. Former CMO of Walgreens. Holds a medical degree from Dartmouth Medical School. | |
Melissa Baird Executive | COO | None | Joined Hims & Hers in February 2018; previously held leadership roles at Draper James, Bonobos, and Zulily. Holds a B.S. in Biological Sciences from the University of Missouri. | |
Mike Chi Executive | Chief Commercial Officer | None | Joined Hims & Hers in April 2021; previously held leadership roles at Zola, INTERMIX, and Gilt Groupe. Brings over 20 years of experience in consumer internet. | |
Soleil Boughton Executive | Chief Legal Officer | Board Member at CaringBridge | Joined Hims & Hers in October 2018; previously in-house counsel at Google Cloud Healthcare and a partner at Jones Day. Holds a B.A. from Pomona College and a J.D. from UCLA. | |
Yemi Okupe Executive | CFO | None | Joined Hims & Hers in January 2022; previously held senior financial roles at Uber, Hipcamp, and PayPal. Holds an MBA from Stanford and is a CFA and CPA. | |
Andrea Perez Board | Director | Advisory roles for startups in services and technology sectors | Former SVP at Sony Interactive Entertainment and VP/GM at Nike. Co-founder of Women of Nike employee group. Holds a B.A. in Economics from Harvard. | |
Anja Manuel Board | Director | Board Member at Ripple Labs; Member of U.S. Defense Department Policy Board | Co-founder of Rice, Hadley, Gates & Manuel LLC; Executive Director of Aspen Strategy Group. Extensive experience in foreign policy and governance. | |
Christiane Pendarvis Board | Director | Co-CEO of PATTERN Beauty; Board Member at Hootsuite | Former Co-President of Savage X Fenty; extensive experience in DTC and retail operations. Holds a B.A. from Harvard and an MBA from UNC Kenan-Flagler. | |
Christopher Payne Board | Director | Board Member at Gogo Inc. | Former President and COO of DoorDash; previously held leadership roles at Tinder, eBay, Microsoft, and Amazon. Holds a B.S. in Commerce and English from the University of Virginia. | |
David Wells Board | Lead Independent Director | Board Member at The Trade Desk and Wise PLC | Former CFO of Netflix (2010-2019); extensive experience in financial planning and analysis. Holds a B.S. from the University of Virginia and an MBA from the University of Chicago. | |
Deb Autor Board | Director | None | Former FDA official; serves on Hims & Hers Risk Committee. Also provides consulting services to Hims & Hers. Holds extensive regulatory and compliance expertise. | |
Dr. Delos Cosgrove Board | Director | Board Member at American Well Corp. (Amwell) and View, Inc. | Former CEO of Cleveland Clinic (2004-2017); currently an Executive Advisor at Cleveland Clinic. Holds a medical degree and extensive experience in healthcare leadership. | |
Kåre Schultz Board | Director | None | Former CEO of Teva Pharmaceuticals; extensive experience in pharmaceutical and healthcare industries. Appointed to Hims & Hers board in July 2024. |
- Given the recent gross margin degradation driven by the scaling of your weight loss specialty, particularly GLP-1 offerings, how do you plan to offset these margin pressures going forward, and what are your expectations for gross margins as this segment continues to grow?
- With the evolving regulatory landscape around compounded GLP-1 medications and potential shortages of name-brand options, how do you anticipate these factors impacting your weight loss specialty, and what steps are you taking to mitigate associated risks?
- You mentioned significant investments in both 503(a) and 503(b) facilities to support personalized weight loss solutions; can you elaborate on how these investments align with your capital allocation priorities and their expected impact on operational efficiency?
- Considering that higher-priced weight loss solutions contribute to the increased average revenue per subscriber, how sustainable is this growth, and what strategies are you implementing to ensure long-term retention and diversification across other specialties?
- As you broaden your personalized and multi-specialty offerings, what challenges do you foresee in maintaining high retention rates and customer satisfaction, especially with the integration of new treatments like GLP-1s, and how do you plan to address them?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MedisourceRx (Seaview Enterprises LLC) | 2024 | The acquisition closed on September 5, 2024 for a total purchase price of $31.0 million structured as $15.5 million in cash and 976,341 shares of Class A common stock, and it enhanced Hims & Hers’ capabilities by acquiring a 503B compounding outsourcing facility with key allocations including $28.6 million for the pharmacy license and $1.8 million in goodwill, with post-closing adjustments within 90 days. |
Honest Health Limited (HHL) | 2021 | Acquired in June 2021 for $4.8 million (including earn-out components settled partly in 2024 via cash and stock-based compensation), the deal was aimed at broadening Hims & Hers’ presence in the UK through strategic health and wellness products, with ongoing stock compensation and earn-out adjustments finalized in 2024. |
YoDerm, Inc. (Apostrophe) | 2021 | Completed in July 2021 for a total purchase price of $131.6 million—a blend of $48.2 million in cash, 8,074,935 shares of Class A common stock, and contingent earn-out—this acquisition expanded Hims & Hers’ dermatology and personalized healthcare offerings by integrating Apostrophe’s compounding pharmacy operations and recognizing $2.7 million in goodwill. |
Recent press releases and 8-K filings for HIMS.
- Securities class action lawsuits have been filed against Hims & Hers Health, Inc. and certain executives, representing investors who purchased securities between April 29, 2025, and June 23, 2025. The lead plaintiff deadline is August 25, 2025.
- The lawsuits follow Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, citing concerns over "deceptive" marketing and "illegal compounding" of Wegovy®.
- Plaintiffs allege that Hims & Hers issued misleading assurances to investors regarding its regulatory compliance and the robustness of revenue from its GLP-1 drug offerings.
- Following Novo Nordisk's announcement, Hims & Hers shares crashed 30%.
- Earlier, on February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved, which constrained Hims & Hers' ability to continue selling compounded semaglutide.
- A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) on behalf of investors who purchased securities between April 29, 2025, and June 23, 2025.
- The lawsuit alleges that Hims engaged in "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy," leading to the termination of its collaboration with Novo Nordisk on June 23, 2025.
- Following the news of the partnership termination, HIMS's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.
- Investors who suffered losses on HIMS investments are urged to contact Glancy Prongay & Murray LLP, with a lead plaintiff motion deadline of August 25, 2025.
- Securities class action lawsuits were filed against Hims & Hers Health, Inc. and certain executives on June 25, 2025, on behalf of investors who purchased securities between April 29, 2025, and June 23, 2025.
- The lawsuits stem from Novo Nordisk's termination of its collaboration with Hims & Hers due to concerns about its sales and "deceptive" marketing of Wegovy®.
- Allegations include the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®, which allegedly exposed patients to unknown risks and threatened the company's relationship with Novo Nordisk.
- Following Novo Nordisk's announcement on June 23, 2025, Hims & Hers shares crashed 30% lower.
- A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws.
- The complaint alleges Hims & Hers misrepresented its collaboration with Novo Nordisk, including claims about selling Wegovy and compounded semaglutide, and compliance with FDA regulations.
- On June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy" and failure to adhere to laws prohibiting mass sales of compounded drugs.
- Following this news, Hims & Hers' stock price fell $22.24 per share, or more than 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025.
- Investors have until August 25, 2025, to ask the Court to be appointed to lead the case.
- A class-action lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws.
- The complaint alleges that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and its compliance with FDA regulations regarding the sale of Wegovy and compounded semaglutide.
- On June 23, 2025, Novo Nordisk announced the termination of its collaboration with Hims & Hers, citing "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy".
- Following this news, Hims & Hers' stock price fell by $22.24 per share, or more than 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025.
- Investors have until August 25, 2025, to ask the Court to be appointed to lead the case.
- Hims & Hers stock crashed 30% after Novo Nordisk accused the company of deceptive marketing. Hims & Hers denies the accusation.
- The primary risk to Hims & Hers stems from its weight loss drug business, which constitutes over 50% of its current revenue. This segment operates in a gray area by compounding patented drugs through personalization and microdosing, which is the core concern for Novo Nordisk.
- This issue poses a significant risk to the company's future, especially as its traditional core business (erectile dysfunction and baldness drugs) has been declining or decelerating.
- Novo Nordisk terminated its partnership with Hims & Hers over allegations of selling unsafe knock-off drugs and compounded GLP-1s in violation of FDA regulations, citing false marketing and patient safety risks .
- The move followed claims of illegal compounding and deceptive marketing of semaglutide-based weight-loss drugs, triggering a 20–32% intraday stock drop and investor fallout .
- Multiple law firms, including Howard G. Smith, Kessler Topaz Meltzer & Check and Block & Leviton, are probing potential federal securities violations and whether Hims & Hers misled investors .
- Loss of access to Wegovy could negatively impact Hims & Hers’ revenue and market position, while Novo Nordisk plans to work with other telehealth providers .
- 2030 targets announced: The company outlined ambitions to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, reflecting confidence in its personalization strategy and growth runway.
- Enhanced personalization driving engagement: The call highlighted how personalized offerings increased the share of subscribers on customized products from less than 15% to over 60% in Q1, reinforcing consumer demand.
- Strengthening weight loss and specialty portfolios: Strategic partnerships, including a collaboration with Novo on weight loss treatments and growth across specialties such as dermatology and sexual health, were emphasized as key drivers.
- Investments in lab diagnostics and M&A activities: The firm is scaling at-home lab testing to remove service barriers and is executing a disciplined M&A framework to expand strategic capabilities and international reach.
- Hims & Hers Health, Inc. intends to offer $450 million aggregate principal amount of convertible senior notes due 2030, with an option to purchase an additional $67.5 million in notes.
- The proceeds are aimed at accelerating global expansion, funding organic growth and strategic acquisitions, and investing in AI-driven healthcare initiatives.
- Robust Q1 Performance: Revenue grew 111% YoY to $586.0 million, demonstrating strong financial momentum .
- EBITDA & Margin Excellence: Delivered $91M in Adjusted EBITDA at nearly 16% margin, reflecting improved unit economics .
- Subscriber Growth: Expanded the subscriber base to 2.4 million (up 38% YoY) driven by effective acquisition and personalized offerings .
- Guidance & Long-Term Outlook: Reaffirmed full-year guidance of $2.3–2.4 billion in revenue and set 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA .
- Strategic Expansion & Innovation: Launched liraglutide in the weight loss category and formed a collaboration with Novo Nordisk to introduce branded Wegovy .
- Top-line Growth Focus: Emphasized subscriber acquisition, targeted marketing, and operational efficiency, with monthly revenue per subscriber rising to $84 .
- Financial Resilience: Maintained a strong cash position with operating cash flow of $323M and a debt-free balance sheet .